PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Bone Biologics Corporation (BBLG)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS0980703039
CUSIP098070303
SectorHealthcare
IndustryMedical Devices

Highlights

Market Cap$1.42M
EPS-$34.01
EBITDA (TTM)-$824.96K
Year Range$1.56 - $72.00
Target Price$19.50
Short %1.78%
Short Ratio0.10

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Bone Biologics Corporation

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Bone Biologics Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-40.00%-20.00%0.00%20.00%40.00%NovemberDecember2024FebruaryMarchApril
-50.00%
18.81%
BBLG (Bone Biologics Corporation)
Benchmark (^GSPC)

S&P 500

Returns By Period

Bone Biologics Corporation had a return of -64.60% year-to-date (YTD) and -97.13% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-64.60%5.05%
1 month-28.89%-4.27%
6 months-64.91%18.82%
1 year-97.13%21.22%
5 years (annualized)-95.95%11.38%
10 years (annualized)N/A10.42%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-19.69%-32.51%-13.06%
20234.89%-26.07%-22.10%38.14%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of BBLG is 9, indicating that it is in the bottom 9% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.

The Risk-Adjusted Performance Rank of BBLG is 99
Bone Biologics Corporation(BBLG)
The Sharpe Ratio Rank of BBLG is 1919Sharpe Ratio Rank
The Sortino Ratio Rank of BBLG is 33Sortino Ratio Rank
The Omega Ratio Rank of BBLG is 33Omega Ratio Rank
The Calmar Ratio Rank of BBLG is 11Calmar Ratio Rank
The Martin Ratio Rank of BBLG is 2222Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Bone Biologics Corporation (BBLG) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


BBLG
Sharpe ratio
The chart of Sharpe ratio for BBLG, currently valued at -0.65, compared to the broader market-2.00-1.000.001.002.003.00-0.65
Sortino ratio
The chart of Sortino ratio for BBLG, currently valued at -2.24, compared to the broader market-4.00-2.000.002.004.00-2.24
Omega ratio
The chart of Omega ratio for BBLG, currently valued at 0.71, compared to the broader market0.501.001.500.71
Calmar ratio
The chart of Calmar ratio for BBLG, currently valued at -0.97, compared to the broader market0.001.002.003.004.005.00-0.97
Martin ratio
The chart of Martin ratio for BBLG, currently valued at -1.15, compared to the broader market0.0010.0020.0030.00-1.15
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.81, compared to the broader market-2.00-1.000.001.002.003.001.81
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.64, compared to the broader market-4.00-2.000.002.004.002.64
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.31, compared to the broader market0.501.001.501.32
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.38, compared to the broader market0.001.002.003.004.005.001.38
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.21, compared to the broader market0.0010.0020.0030.007.21

Sharpe Ratio

The current Bone Biologics Corporation Sharpe ratio is -0.65. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
-0.65
1.81
BBLG (Bone Biologics Corporation)
Benchmark (^GSPC)

Dividends

Dividend History


Bone Biologics Corporation doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-100.00%
-4.64%
BBLG (Bone Biologics Corporation)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Bone Biologics Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Bone Biologics Corporation was 100.00%, occurring on Apr 22, 2024. The portfolio has not yet recovered.

The current Bone Biologics Corporation drawdown is 100.00%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Aug 17, 2017709Apr 22, 2024
-78.45%Aug 18, 201618Jan 3, 201717Jul 18, 201735
-2%Jul 22, 20161Jul 22, 20161Aug 8, 20162

Volatility

Volatility Chart

The current Bone Biologics Corporation volatility is 20.70%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%70.00%NovemberDecember2024FebruaryMarchApril
20.70%
3.30%
BBLG (Bone Biologics Corporation)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Bone Biologics Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items